Madrigal Pharmaceuticals (MDGL) vs Mirum Pharmaceuticals (MIRM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Mirum Pharmaceuticals (MIRM) has outperformed Madrigal Pharmaceuticals (MDGL) over the past year, gaining 16.5% versus a gain of 10.1%. Over five years, MDGL leads with a +447.5% price change compared with +402.4% for MIRM. Madrigal Pharmaceuticals is the larger company by market cap ($10.90 billion vs $5.58 billion), about 2.0 times the size.
Mirum Pharmaceuticals converts more of its revenue into profit, with a net margin of -4.5% versus -30.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDGL | MIRM |
|---|---|---|
| Share price | $471.75 | $86.01 |
| Market cap | $10.90B | $5.58B |
| 1-day change | -1.08% | +5.73% |
| YTD return | -18.99% | +8.89% |
| 1-year return | +10.14% | +16.51% |
| 5-year return | +447.46% | +402.39% |
| Forward P/E | 49.01 | — |
| EPS (TTM) | $-12.85 | $-14.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $958.40M | $521.31M |
| Revenue growth (YoY) | +432.05% | +54.74% |
| Net income (latest FY) | $-288.28M | $-23.36M |
| Operating margin | -31.31% | -4.25% |
| Net margin | -30.08% | -4.48% |
| 52-week high | $615.00 | $130.00 |
| 52-week low | $393.61 | $63.23 |
| Distance from 52-week high | -23.29% | -33.84% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +44.59% | +69.50% |
| Average volume | 289.24K | 695.76K |
| Shares outstanding | 23.10M | 64.93M |
| Employees | 915 | 433 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Mirum Pharmaceuticals is more profitable, keeping -4.5 cents of every revenue dollar as net income versus -30.1 cents for Madrigal Pharmaceuticals.
- Madrigal Pharmaceuticals grew revenue faster in its latest fiscal year (+432.05% vs +54.74%).
About Madrigal Pharmaceuticals
MDGL stock →Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.
Healthcare · Biotechnology · 915 employees
About Mirum Pharmaceuticals
MIRM stock →Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
Healthcare · Biotechnology · 433 employees
MDGL vs MIRM FAQ
Which is bigger, Madrigal Pharmaceuticals or Mirum Pharmaceuticals?
Madrigal Pharmaceuticals (MDGL) is larger, with a market capitalization of $10.90B compared with $5.58B for Mirum Pharmaceuticals (MIRM).
Which stock has performed better over the past year, MDGL or MIRM?
MIRM returned +16.51% over the past 12 months, compared with +10.14% for MDGL (price return, excluding dividends). Past performance does not predict future results.
Are Madrigal Pharmaceuticals and Mirum Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.